Madrigal Pharmaceuticals Files 8-K
Ticker: MDGL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1157601
Sentiment: neutral
Topics: disclosure, financials, operations
TL;DR
Madrigal Pharma dropped an 8-K, check financials and ops updates.
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Madrigal Pharmaceuticals is providing updates on its financial status and operational results to the SEC, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of operational and financial information without any immediate negative or positive catalysts mentioned.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- SYNTA PHARMACEUTICALS CORP (company) — Former Company Name
- January 13, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Pennsylvania (state) — Principal Executive Offices Location
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not specify the actual financial figures or operational details within this excerpt.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on January 13, 2025.
What is the principal executive office address for Madrigal Pharmaceuticals, Inc.?
The principal executive offices are located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428.
What is the telephone number for Madrigal Pharmaceuticals, Inc.?
The registrant's telephone number, including area code, is (267) 824-2827.
Has Madrigal Pharmaceuticals, Inc. undergone any previous name changes?
Yes, the company was formerly known as SYNTA PHARMACEUTICALS CORP, with a date of name change on August 15, 2001.
Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2025-01-13 06:50:34
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MDGL The Nasdaq
- $100 million — (resmetirom) net sales in the range of $100 million to $103 million and $177 million to $18
- $103 million — t sales in the range of $100 million to $103 million and $177 million to $180 million, respe
- $177 million — nge of $100 million to $103 million and $177 million to $180 million, respectively. The Comp
- $180 m — ion to $103 million and $177 million to $180 million, respectively. The Company also r
- $931 million — marketable securities of approximately $931 million as of December 31, 2024. A copy of the
Filing Documents
- d925380d8k.htm (8-K) — 27KB
- d925380dex991.htm (EX-99.1) — 21KB
- g925380g0112055637388.jpg (GRAPHIC) — 3KB
- 0001193125-25-004939.txt ( ) — 183KB
- mdgl-20250113.xsd (EX-101.SCH) — 3KB
- mdgl-20250113_lab.xml (EX-101.LAB) — 18KB
- mdgl-20250113_pre.xml (EX-101.PRE) — 11KB
- d925380d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Madrigal Pharmaceuticals, Inc., dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi C. Dier Name: Mardi C. Dier Title: Senior Vice President and Chief Financial Officer Date: January 13, 2025